Search research articles
Contact Us
Filters
Showing results (21-30 of 26) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 26 results.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
April 28, 2004
Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4
Jack W Coburn, Hla M Maung, Logan Elangovan, et al.
Public Health Action
|
April 10, 2019
Tuberculosis-diabetes screening: how well are we doing? A mixed-methods study from North India
A Majumdar, E Wilkinson, P K Rinu, et al.
Science Advances
|
February 26, 2020
On the glacial-interglacial variability of the Asian monsoon in speleothem δ<sup>18</sup>O records
G Liu, X Li, H-W Chiang, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
September 8, 2000
Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism
J M Frazão, L Elangovan, H M Maung, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
March 3, 2001
Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison
H M Maung, L Elangovan, J M Frazão, et al.
Life Sciences in Space Research
|
August 19, 2019
Advances in space radiation physics and transport at NASA
John W Norbury, Tony C Slaba, Sukesh Aghara, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 26) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 26 results.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
April 28, 2004
Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4
Jack W Coburn, Hla M Maung, Logan Elangovan, et al.
Public Health Action
|
April 10, 2019
Tuberculosis-diabetes screening: how well are we doing? A mixed-methods study from North India
A Majumdar, E Wilkinson, P K Rinu, et al.
Science Advances
|
February 26, 2020
On the glacial-interglacial variability of the Asian monsoon in speleothem δ<sup>18</sup>O records
G Liu, X Li, H-W Chiang, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
September 8, 2000
Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism
J M Frazão, L Elangovan, H M Maung, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
March 3, 2001
Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison
H M Maung, L Elangovan, J M Frazão, et al.
Life Sciences in Space Research
|
August 19, 2019
Advances in space radiation physics and transport at NASA
John W Norbury, Tony C Slaba, Sukesh Aghara, et al.
Page
of 3